Options to treat late-stage castration-resistant prostate cancer continued to increase in 2011, as three agents with different mechanisms of action prolonged life and a fourth reduced the morbidity of skeletal metastases. These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47, a7003 (2011).
Medivation. Medivation and Astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer [online], (2011).
Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).
Yu, E. Y. et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15, 7421–7428 (2009).
Hussain, M. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial [abstract]. J. Clin. Oncol. 29 (Suppl.), a4516 (2011).
Hugosson, J. et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11, 725–732 (2010).
Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).
Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).
Chou, R. et al. Screening for prostate cancer: a review of the evidence for the U. S. Preventive Services Task Force. Ann. Intern. Med. 155, 762–771 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H. I. Scher acts a as a consultant for Amgen, Dendreon, Exelixis, Medivation, Ortho Biotech Oncology Research & Development and Sanofi-Aventis. He also receives grant support from Medivation and Ortho Biotech Oncology Research & Development. Y. Chen declares no competing interests.
Rights and permissions
About this article
Cite this article
Chen, Y., Scher, H. Hitting old targets better and identifying new targets. Nat Rev Clin Oncol 9, 70–72 (2012). https://doi.org/10.1038/nrclinonc.2011.213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.213
This article is cited by
-
Prostate cancer biomarker: a key field to explore
Asian Journal of Andrology (2013)